XOMA (NASDAQ:XOMA) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of XOMA (NASDAQ:XOMAFree Report) from a hold rating to a buy rating in a research report sent to investors on Saturday.

A number of other research firms also recently commented on XOMA. HC Wainwright reaffirmed a “buy” rating and issued a $104.00 price target on shares of XOMA in a research note on Wednesday, May 28th. Benchmark started coverage on shares of XOMA in a report on Thursday, April 17th. They issued a “buy” rating and a $35.00 target price on the stock.

View Our Latest Analysis on XOMA

XOMA Stock Performance

NASDAQ XOMA opened at $23.85 on Friday. XOMA has a 52-week low of $18.35 and a 52-week high of $35.00. The firm has a 50-day moving average of $23.91 and a 200-day moving average of $24.64. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The stock has a market cap of $285.41 million, a PE ratio of -6.85 and a beta of 0.94.

XOMA (NASDAQ:XOMAGet Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.32. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The firm had revenue of $15.91 million during the quarter, compared to the consensus estimate of $6.75 million. On average, sell-side analysts anticipate that XOMA will post -1.41 EPS for the current year.

Insider Activity

In related news, CIO Bradley Sitko purchased 4,134 shares of XOMA stock in a transaction dated Friday, March 21st. The shares were bought at an average cost of $23.89 per share, for a total transaction of $98,761.26. Following the purchase, the executive now owns 10,484 shares in the company, valued at approximately $250,462.76. This trade represents a 65.10% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the company’s stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $27.10, for a total transaction of $10,642,793.30. Following the transaction, the insider now owns 1,267,545 shares of the company’s stock, valued at approximately $34,350,469.50. This represents a 23.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have acquired 29,312 shares of company stock worth $735,061. Insiders own 9.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Woodline Partners LP grew its holdings in XOMA by 63.9% during the 4th quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company’s stock worth $4,107,000 after acquiring an additional 60,927 shares during the last quarter. Nuveen LLC acquired a new position in shares of XOMA during the first quarter worth $286,000. CM Management LLC grew its stake in shares of XOMA by 16.4% in the first quarter. CM Management LLC now owns 64,000 shares of the biotechnology company’s stock worth $1,276,000 after purchasing an additional 9,000 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of XOMA by 238.9% in the fourth quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company’s stock worth $318,000 after purchasing an additional 8,522 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in XOMA in the fourth quarter valued at $206,000. 95.92% of the stock is currently owned by institutional investors.

About XOMA

(Get Free Report)

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

See Also

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.